HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) shares saw strong trading volume on Wednesday . 105,064 shares were traded during mid-day trading, an increase of 5% from the previous session's volume of 100,338 shares.The stock last traded at $16.16 and had previously closed at $15.93.
Wall Street Analyst Weigh In
A number of analysts have commented on the stock. Wall Street Zen upgraded shares of HUTCHMED from a "buy" rating to a "strong-buy" rating in a report on Friday, June 27th. HSBC downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Read Our Latest Stock Analysis on HUTCHMED
HUTCHMED Price Performance
The company has a quick ratio of 2.70, a current ratio of 2.83 and a debt-to-equity ratio of 0.08. The stock's fifty day simple moving average is $14.90 and its 200 day simple moving average is $14.69.
Institutional Trading of HUTCHMED
Several hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in shares of HUTCHMED by 8.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company's stock valued at $1,413,000 after buying an additional 7,342 shares during the period. Jane Street Group LLC boosted its position in HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company's stock valued at $3,343,000 after buying an additional 124,771 shares during the period. Vident Advisory LLC lifted its position in shares of HUTCHMED by 78.3% during the 1st quarter. Vident Advisory LLC now owns 19,728 shares of the company's stock worth $297,000 after purchasing an additional 8,664 shares during the last quarter. XY Capital Ltd lifted its position in shares of HUTCHMED by 142.4% during the 1st quarter. XY Capital Ltd now owns 113,136 shares of the company's stock worth $1,702,000 after purchasing an additional 66,460 shares during the last quarter. Finally, Crossmark Global Holdings Inc. raised its stake in HUTCHMED by 31.4% during the 1st quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company's stock worth $367,000 after acquiring an additional 5,829 shares in the last quarter. Hedge funds and other institutional investors own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
